Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage

Risk of peripheral neuropathy is already in labeling and FDA doesn’t want to require a black box, illustrating the agency’s ongoing challenge to fully communicate risks without unduly limiting access or use.